video corpo

OptiLIGHT

OptiLIGHT

OptiLIGHT

Product catalog summary
Introduction
The document introduces OptiLIGHT, a light therapy device approved by the FDA for managing dry eye disease due to Meibomian Gland Dysfunction (MGD). It highlights the device's ability to improve patient care and expand medical practices with new treatment options.

Specifications
  • Material: Polyester with adhesive back (3M 7871 - UL MH16411 or equivalent).
  • Dimensions: 51 x 56 x 52 cm (without ResurFX) and 51 x 56 x 65 cm (with ResurFX).
  • Weight: 45 kg (without ResurFX) and 60 kg (with ResurFX).
  • Electrical requirements: Single phase, dedicated line.
  • OptiLIGHT Spectrum: 590 nm to 755 nm.
  • Maximal Fluence: 35 J/cm².
  • Pulse Duration and Delay: Multiple Sequential Pulsing with up to 1 Hz repetition rate.

Clinical Benefits
OptiLIGHT is designed to break the cycle of inflammation in dry eye disease by decreasing inflammatory markers, improving tear breakup time, and restoring meibomian gland functionality. Clinical studies have shown significant improvements in these areas.

Usage and Indications
In the EU, OptiLIGHT is indicated for evaporative dry eye disease due to MGD. In the US, it is approved for improving signs of dry eye disease in patients aged 22 and older with moderate to severe symptoms. The device should be used as an adjunct to other treatments like meibomian gland expression and artificial tear lubricants.

Contraindications
OptiLIGHT is contraindicated for patients with recent ocular or eyelid surgery, uncontrolled infections, history of cold sores, use of photosensitive medication, recent radiation therapy, and certain systemic conditions. Protective eyewear is mandatory during treatment.

Technical Parameters
The device operates within a wavelength range of 400-1200 nm with a maximum fluence of 56 J/cm² and pulse duration of 4-20 ms. It complies with IEC60601-2-57 Ed 1 standards.

Contact Information
Contact details for Lumenis offices in Asia, Americas, EMEA, and Japan are provided for further inquiries and support.
See more

Catalog excerpts

OptiLIGHT-1

RELEASE NEW DRAWING Update label – wording fix Mor Bisk Vadim Andreyev 1. Material: Polyester. 2. Adhesive back: 3M 7871 - UL MH16411 or equivalent. 3. Background colors: Yellow: C=0; M=0; Y=100; K=0. 4. Graphics symbols color: Black over background. 5. Text color: Black over background. 6. Text font: Arial.

 Open the catalog to page 1
OptiLIGHT-2

E EVATING DRY EYE MANAGEMENT LUMENIS PUTS THE POWER TO MANAGE DRY EYE DISEASE IN THE PALM OF YOUR HAND impacting vision and quality of life as well as the outcomes of ophthalmic surgeries. 1 Introducing the first and only light Therapy, FDA-approved for management of dry eye disease due to meibomian gland dysfunction (MGD), the leading cause of dry eye disease.2 With clinically proven, patented technologies, the power for treating dry eye disease is in the palm of your hand. Get the safe, precise, therapy patients need to manage dry eye disease with OptiLIGHT.

 Open the catalog to page 2
OptiLIGHT-3

which the authorized recipient agrees to protect & not to disclose. ELEVATE YOUR PRACTICE ELEVATE PATIENT CARE With OptiLIGHT in your practice, your patients can count on you for a medical solution to a frustrating condition. OptiLIGHT is easy to use, with minimal training and set-up. OptiLIGHT also helps expand your practice with a new line of treatment and upgrade to aesthetics treatments. Lumenis is here to help, with clinical training and marketing support to enhance your growth. Each treatment takes about 15 minutes, so you can easily integrate OptiLIGHT into the workflow. Patients achieve...

 Open the catalog to page 3
OptiLIGHT-4

BREAK THE DRY EYE VICIOUS CYC E OF INF AMMATION With every pulse of light, this first-of-its-kind light-based treatment works to control the inflammatory process and to improve signs of dry eye disease due to MGD. Peer-reviewed clinical studies show that Lumenis IPL with OPT addresses the dry eye vicious cycle of inflammation: * Decreases the level of pro-inflammatory mediators to inhibit inflammation 3 Restores meibomian glands functionality 4,8 Alleviates the abnormal blood vessels that perpetuate inflammation 5,6 Increases tear breakup time 9 Decreases the population of Demodex mites, which...

 Open the catalog to page 4
OptiLIGHT-5

EVERY E EMENT DESIGNED FOR A PRECISE AND COMFORTAB E DRY EYE PROCEDURE PATENTED OPT® HANDPIECE Treat the delicate facial contours of each individual patient. The patented OPT® handpiece is easily customized to fit every curve and outline. ERGONOMIC IPL HANDPIECE Treat wider areas safely and comfortably using the IPL handpiece with patented SapphireCoolTM PERSONALIZED EXPERIENCE FOR SAFETY AND COMFORT Experience optimal energy control at the tip of your OptiLIGHT, for targeted,precise, hygienic and controlled treatment, especially for delicate areas. PROVEN SETTINGS AND PROTOCOLS Utilize embedded...

 Open the catalog to page 5
OptiLIGHT-6

TECHNICA PARAMETERS System Specifications Dimensions [without ResurFX] Dimensions [with ResurFX] Weight [without ResurFX] OptiLIGHT Spectrum ExpertFilters* Lightguides Maximal Fluence** Pulse Duration** Pulse Delay** Weight [with ResurFX] Electrical requirements Pulse Characteristic Multiple Sequential Pulsing Repetition Rate Spot Size single phase, dedicated line Indication for Use: In EU: Evaporative Dry Eye Disease (DED), also known as dry eye syndrome or lipid tear deficiency, due to Meibomian Gland Dysfunction (MGD). In US: Improvement of signs of Dry Eye Disease (DED) due to Meibomian Gland...

 Open the catalog to page 6

All Lumenis catalogs and technical brochures

  1. AcuPulse

    5  Pages

  2. NuEra Tight

    8  Pages

  3. Stellar M22

    8  Pages

*Prices are pre-tax. They exclude delivery charges and customs duties and do not include additional charges for installation or activation options. Prices are indicative only and may vary by country, with changes to the cost of raw materials and exchange rates.